Erythropoietin composition
US4835260A · kind A · utility
72Cited by
2References
4Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Mar 20, 1987 |
| Grant date | May 30, 1989 |
| Priority date | — |
| Expiry date | Mar 20, 2007 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/83
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A new improved glycoprotein having erythropoietin-type activity is disclosed. The substrate is characterized by amino acid sequence substantially identical to the amino acid sequence of native human erythropoietin wherein the methionine-54 is replaced with leucine. DNA encoding for the EPO-substance and expression vectors incorporating the same are disclosed. Therapeutic compositions and methods for treatment of anemic conditions are described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.